Skip to main contentSkip to footer
T

Trialytics

How it worksAboutFAQBlog
Home/Biomarkers/ENDOGENOUS RETROVIRUS GROUP K, MEMBER 4

ENDOGENOUS RETROVIRUS GROUP K, MEMBER 4 clinical trials

1 active trial require this biomarker. Describe your situation to see which ones you may be eligible for.

  • First-in-human, Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) Alone or in Combination With Pembrolizumab in Stage II-- III Triple Negative Breast Cancer Following Standard Therapy ( VITAL-TNBC )RECRUITINGPhase 1NCT07652242

Guides for people searching for a trial

  • How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
  • Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
  • How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
  • What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
  • 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
  • You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.

Showing active trials that require “ENDOGENOUS RETROVIRUS GROUP K, MEMBER 4”. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.

T

Trialytics

Clinical trials explained in plain language.

Product

  • How it Works
  • Search Trials
  • Browse by Condition
  • Browse by Biomarker

Company

  • About
  • Blog
  • Contact

Legal

  • Privacy Policy
  • Terms of Use
  • HIPAA Authorization
  • Request HIPAA Compliance Statement

© 2026 Trialytics. All rights reserved.